Cytarabine
- Generic Name
- Cytarabine
- Brand Names
- Cytosar, Vyxeos
- Drug Type
- Small Molecule
- Chemical Formula
- C9H13N3O5
- CAS Number
- 147-94-4
- Unique Ingredient Identifier
- 04079A1RDZ
- Background
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
- Indication
For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia
- Associated Therapies
- -
A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2019-10-04
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- ECOG-ACRIN Cancer Research Group
- Target Recruit Count
- 360
- Registration Number
- NCT04115631
- Locations
- ๐บ๐ธ
Northwestern Medicine Cancer Center Warrenville, Warrenville, Illinois, United States
๐บ๐ธProvidence Newberg Medical Center, Newberg, Oregon, United States
๐บ๐ธPrisma Health Cancer Institute - Easley, Easley, South Carolina, United States
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)
- First Posted Date
- 2019-10-03
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- Kartos Therapeutics, Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT04113616
- Locations
- ๐ฉ๐ช
University Hospital Jena, Jena, Germany
๐ง๐ชCliniques universitaires Saint-Luc, Brussels, Belgium
๐ง๐ชUZ Gent, Ghent, Belgium
A Clinical Trial to Assess the Efficacy and Safety of the Combination of a Drug Call Quizartinib With Chemotherapy (FLAG-IDA) in Patients With Acute Myeloid Leukemia That Has Not Responded to the First Treatment or That Has Returned After the First Treatment
- Conditions
- Interventions
- First Posted Date
- 2019-10-02
- Last Posted Date
- 2022-03-14
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 63
- Registration Number
- NCT04112589
- Locations
- ๐ช๐ธ
Hospital General Universitario de Alicante, Alicante, Spain
๐ช๐ธInstitut Catalร D'Oncologia-Hospital Germans Trias I Pujol, Badalona, Spain
๐ช๐ธInstitut Catalร D'Oncologia-Hospital Duran I Reynals, Bellvitge, Spain
Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)
- Conditions
- Interventions
- First Posted Date
- 2019-09-27
- Last Posted Date
- 2022-01-21
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 273
- Registration Number
- NCT04107727
- Locations
- ๐ช๐ธ
Hospital Universitari i Politecnic La Fe, Valencia, Spain
๐ช๐ธHospital Clรญnico Universitario de Valladolid, Valladolid, Spain
๐ช๐ธHospital Universitario Miguel Servet, Zaragoza, Spain
A Study of Ficlatuzumab With HiDAC and HiDAC Alone in Adults With Relapsed or Refractory Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2019-09-24
- Last Posted Date
- 2020-03-31
- Lead Sponsor
- AVEO Pharmaceuticals, Inc.
- Registration Number
- NCT04100330
Comparison of Therapies Before Stem Cell Transplantation in Patients With Higher Risk MDS and Oligoblastic AML
- Conditions
- Interventions
- First Posted Date
- 2019-08-19
- Last Posted Date
- 2023-10-11
- Lead Sponsor
- GWT-TUD GmbH
- Target Recruit Count
- 150
- Registration Number
- NCT04061239
- Locations
- ๐ฆ๐น
Uniklinikum Salzburg - Landeskrankenhaus, Salzburg, Austria
๐ฉ๐ชUniversitรคtsklinikum Augsburg, Augsburg, Germany
๐ฉ๐ชKlinikum Frankfurt (Oder) GmbH, Frankfurt, Germany
Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- Conditions
- Recurrent Acute Biphenotypic LeukemiaAcute Myeloid LeukemiaRecurrent Acute Myeloid LeukemiaBlasts 20 Percent or More of Bone Marrow Nucleated CellsRefractory Acute Myeloid LeukemiaRefractory High Risk Myelodysplastic SyndromeHigh Risk Myelodysplastic SyndromeRecurrent High Risk Myelodysplastic Syndrome
- Interventions
- First Posted Date
- 2019-08-07
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 80
- Registration Number
- NCT04047641
- Locations
- ๐บ๐ธ
M D Anderson Cancer Center, Houston, Texas, United States
International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2019-08-02
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- University Hospital Muenster
- Target Recruit Count
- 683
- Registration Number
- NCT04043494
- Locations
- ๐ณ๐ฑ
Princess Maxima Centre for Pediatric Oncology, Utrecht, Netherlands
๐ซ๐ทUnitรฉ d'hรฉmatologie pรฉdiatrique CHRU de Lille - Hรดpital Jeanne de Flandre, Lille, France
๐ง๐ชUZ Antwerpen Kinderhemato-oncologie, Edegem, Belgium
A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors
- First Posted Date
- 2019-07-23
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 38
- Registration Number
- NCT04029688
- Locations
- ๐บ๐ธ
Arkansas Children's Hospital Research Institute, Little Rock, Arkansas, United States
๐บ๐ธLucile Packard Children's Hospital at Stanford University; Thoracic Oncology, Palo Alto, California, United States
๐บ๐ธArnold Palmer Hosp-Children, Orlando, Florida, United States
Medium Dose of Cytarabine and Mitoxantrone
- First Posted Date
- 2019-07-18
- Last Posted Date
- 2019-07-18
- Lead Sponsor
- Shenzhen People's Hospital
- Target Recruit Count
- 250
- Registration Number
- NCT04024241
- Locations
- ๐จ๐ณ
Shenzhen, Shenzhen, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.